Nontuberculous Mycobacterial (NTM) Lung Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Nontuberculous Mycobacterial (NTM) Lung Disease Market Outlook

Thelansis’s “Nontuberculous Mycobacterial (NTM) Lung Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Nontuberculous Mycobacterial (NTM) Lung Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Nontuberculous Mycobacterial (NTM) Lung Disease Overview

Non-tuberculosis mycobacterial (NTM) lung infections are less prevalent than infections caused by Mycobacterium tuberculosis. The transmission of NTM occurs through the inhalation of aerosolized droplets containing the infectious agents. Risk factors for NTM transmission include proximity living, coughing, and failure to use facial masks. Factors such as advanced age, immunosuppression, and corticosteroid usage increase the likelihood of acquiring NTM microorganisms. Following the entry into the body, NTM microorganisms predominantly settle in the lower airways and may induce an inflammatory response characterized by an influx of lymphocytes. This immune response releases cytokines and other mediators, resulting in a pneumonia-like infectious process. Common symptoms of NTM lung infections, such as fever, weight loss, night sweats, decreased appetite, and energy loss, are often nonspecific and vague. The prognosis of NTM lung infections is generally uncertain. Patients with compromised immune systems experience worse outcomes than those with normal immune function. Moreover, the prognosis may vary depending on the specific type of NTM infection. Recent research suggests that patients with NTM infections caused by Mycobacterium avium complex (MAC) generally have a more favorable prognosis than those with other NTM infections. Conversely, patients with Mycobacterial abscessus lung infections have higher mortality rates than patients with different NTM lung infections. Chronic underlying lung diseases, particularly Mycobacterial abscessus infection, in combination with the specific type of NTM infection, appear to be significant predictors of mortality in NTM lung infections. NTM lung disease typically presents in three major clinical forms: fibro-cavitary, nodular bronchiectasis, and hypersensitivity pneumonitis. The clinical manifestations of NTM lung infections can resemble those of other lung infections, such as Mycobacterium tuberculosis, as well as atypical bacterial infections and chronic lung diseases. Infections, neoplasms, and connective tissue diseases are common differential diagnoses similar to NTM lung infections.

• In the USA, the incidence of NTM was estimated to be 4.73 cases per 100,000 annually.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: